Generali Investments Towarzystwo Funduszy Inwestycyjnych Invests $86,000 in DexCom, Inc. (NASDAQ:DXCM)

Generali Investments Towarzystwo Funduszy Inwestycyjnych acquired a new position in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,100 shares of the medical device company’s stock, valued at approximately $86,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of DXCM. Private Advisor Group LLC raised its position in DexCom by 5.7% during the third quarter. Private Advisor Group LLC now owns 11,318 shares of the medical device company’s stock valued at $759,000 after acquiring an additional 608 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in shares of DexCom in the third quarter worth $930,000. State of Alaska Department of Revenue grew its stake in shares of DexCom by 7.3% in the third quarter. State of Alaska Department of Revenue now owns 46,400 shares of the medical device company’s stock worth $3,110,000 after acquiring an additional 3,155 shares during the last quarter. abrdn plc grew its stake in shares of DexCom by 28.4% in the third quarter. abrdn plc now owns 384,646 shares of the medical device company’s stock worth $25,842,000 after acquiring an additional 85,174 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in DexCom by 103.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,306 shares of the medical device company’s stock worth $356,000 after buying an additional 2,692 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In related news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of DexCom stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,083 shares of company stock valued at $3,309,794 in the last 90 days. Insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of a number of analyst reports. Canaccord Genuity Group lifted their price objective on DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Wells Fargo & Company upped their price target on DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Finally, Morgan Stanley upped their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Price Performance

DexCom stock opened at $87.81 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business has a 50-day simple moving average of $84.53 and a 200 day simple moving average of $76.55. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The stock has a market cap of $34.31 billion, a price-to-earnings ratio of 61.41, a PEG ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.